A Double-Blinded and Randomised Study to Compare the Efficacy and Safety of 48-Week Treatment With Clevudine 30 mg qd Versus Lamivudine 100 mg qd for Chronic Hepatitis B Infection

Trial Profile

A Double-Blinded and Randomised Study to Compare the Efficacy and Safety of 48-Week Treatment With Clevudine 30 mg qd Versus Lamivudine 100 mg qd for Chronic Hepatitis B Infection

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2012

At a glance

  • Drugs Clevudine; Lamivudine
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bukwang Pharmaceutical
  • Most Recent Events

    • 25 Jul 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.
    • 19 May 2008 Status changed from recruiting to in progress, from clinicaltrials.gov record.
    • 11 Dec 2007 Interim results from 22 patients presented at Frontiers in Drug Development in Viral Hepatitis (HEP-DART) conference in December 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top